HIV prevention is not all about HIV – using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection
In sub-Saharan Africa, considerable HIV-burden exists among women. Anti-retroviral (ARV) based prevention products could decrease this burden, and their uptake could be increased if they also protect against pregnancy and sexually transmitted infections (STI). A discrete choice experiment (DCE) was undertaken in South Africa (2015) to project the uptake of oral pre-exposure prophylaxis (PrEP), vaginal rings, and injectable long-lasting ARV agents among these women, and how uptake could depend on whether these products protect against pregnancy or STI acquisition. Uptake estimates were used to model how each product could decrease a women’s HIV acquisition risk. The results illustrate that incorporating multiple prevention components into new ARV-based prevention products may increase their uptake and impact among women.
September 2020
Click for full info +Full Info:
Resource Type:
Citation:
In sub-Saharan Africa, considerable HIV-burden exists among women. Anti-retroviral (ARV) based prevention products could decrease this burden, and their uptake could be increased if they also protect against pregnancy and sexually transmitted infections (STI). A discrete choice experiment (DCE) was undertaken in South Africa (2015) to project the uptake of oral pre-exposure prophylaxis (PrEP), vaginal rings, and injectable long-lasting ARV agents among these women, and how uptake could depend on whether these products protect against pregnancy or STI acquisition. Uptake estimates were used to model how each product could decrease a women’s HIV acquisition risk. The results illustrate that incorporating multiple prevention components into new ARV-based prevention products may increase their uptake and impact among women.
Authors:
Vickerman, P.; Quaife, M.; Kilbourne-Brook, M.; Mvundura, M.; Eakle, R.; & Terris-Prestholt, F.
Health Risks(s):
- HIV
- STI / STD
- Unintended Pregnancy
Product type(s):
- ARVs
- Contraceptives
- IVR
Topic(s):
- MPTs
- Product Introduction
- Reproductive Health
- Social
- SRH
Region(s)
- Africa
- Global